BDi Biotechnology Group announced that it has received €1.9 million in funding from Inveready Asset Management, S.G.E.I.C., S.A., Dyadic International, Inc., and other investors
January 03, 2018
Share
BDi Biotechnology Group announced that it has received €1.9 million in seed round of funding co-led by new investors Inveready Asset Management, S.G.E.I.C., S.A. and Dyadic International, Inc. (OTCPK:DYAI) on January 4, 2018.
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
BDi Biotechnology Group announced that it has received €1.9 million in funding from Inveready Asset Management, S.G.E.I.C., S.A., Dyadic International, Inc., and other investors
DYADIC INTERNATIONAL, INC. 
